HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2894-2904

  Press, Michael F ^a   Bernstein, Leslie ^a   Thomas, Patricia A ^a   Meisner, Lorraine F ^a   Zhou, Jian Yuan ^a   Ma, Yanling ^a   Hung, Gene ^a   Robinson, Robert A ^a   Harris, Charles ^a   El Naggar, Adel ^a   Slamon, Dennis J ^a   Phillips, Richard N ^a   Ross, Jeffrey S ^a   Wolman, Sandra R ^a   Flom, Kerry J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; MEMBRANE RECEPTOR; RECEPTOR PROTEIN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER MORTALITY; CANCER RECURRENCE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MARKER GENE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

EID: 18244422222     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2894     Document Type: Article

References (49)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Saffari B, Jones LA, El-Naggar A, et al: Amplification and overexpression of HER-2/neu (c-erb B-2) in endometrial cancers: Correlation with overall survival. Cancer Res 55:5693-5698, 1995
4. Ranzani GN, Pellegata NS, Previdere C, et al: Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. Cancer Res 50:7811-7814, 1990
5. Press MF, Hung G, Pike MC, et al: Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: Correlation with poor prognosis. Cancer Res 54:5675-5682, 1994
6. Press MF, Pike MC, Chazin VR, et al: HER-2/neu expression in node-negative breast cancers: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
7. Press MF, Hung G, Godolphin W, et al: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of expression. Cancer Res 54:2771-2777, 1994
8. Battifora H, Mehta P: The checkerboard tissue block. An improved multi-tissue control block. Lab Invest 63:722-724, 1990
9. Coussens L, Yang-Feng TL, Chen Y-CLE, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
10. Kallioniemi O-P, Kallioniemi A, Kurisu W, et al: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321-5325, 1992
11. Ro J, El-Naggar A, Ro JY, et al: c-erbB-2 amplification in node-negative breast cancer. Cancer Res 49:6941-6944, 1989
12. McGuire WL, Tandon AK, Allred DC, et al: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990
13. Cox C: Fieller's theorem, the likelihood and the delta method. Biometrics 46:709-718, 1990
14. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
15. Shih C, Padhy LC, Murray M, et al: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (London) 290:261-264, 1981
16. Drebin JA, Link VC, Stern DF, et al: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695-706, 1985
17. Muller WJ, Sinn E, Pattengale PK, et al: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115, 1988
18. Semba K, Kamata N, Toyoshima K, et al: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-creB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501, 1985
19. Naber SP, Tsutsumi Y, Yin S, et al: Strategies for the analysis of oncogene overexpression: Studies of the neu oncogene in breast carcinoma. J Clin Pathol 94:125-136, 1990
20. Gullick WJ, Love SB, Wright C, et al: c-erb B-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434-438, 1991
21. Wright C, Angus B, Nicholson S, et al: Expression of c-erb B-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
22. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erb B-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
23. Kallioniemi O-P, Holli K, Visakorpi T, et al: Association of c-erb B-2 oncogene overexpression with high rate of cell proliferation, increased risk for visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
24. Paterson MC, Dietrich KD, Danyluk J, et al: Correlation between c-erb B-2 amplification and risk of early relapse in node-negative breast cancer. Cancer Res 51:556-567, 1991
25. Rilke F, Colnaghi MI, Cascinelli N, et al: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44-49, 1991
26. Winstanley J, Cooke T, Murray GD, et al: The long term prognostic significance of c-erb B-2 in primary breast cancer. Br J Cancer 63:447-450, 1991
27. Allred DC, Lark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
28. Giampietro G, Gullick WJ, Bevilacqua P, et al: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686-695, 1992
29. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049-1056, 1992
30. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936-1942, 1993
31. Gohring, U-J, Aslan-Schadwinkel Y, Scharl A: Expression of the p185neu oncoprotein indicates an unfavorable prognosis in small, node-negative breast cancer without systemic adjuvant treatment (TINO). Geburtsh Frauenheik 53:625-629, 1993
32. Marks JR, Humphrey PA, Wu K, et al: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219:332-341, 1994
33. Tandon AK, Clark GM, Chamness GC, et al: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120-1128, 1989
34. Thor AD, Schwartz LH, Koerner FC, et al: Analysis of c-erb B-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49:7147-7152, 1989
35. Tsuda H, Hirohashi S, Shimosato Y, et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erb B-2/ear-1. Cancer Res 49:3104-3108, 1989
36. Borg A, Tandon AK, Sigurdsson H, et al: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337, 1990
37. Richner J, Gerber HA, Locher GW, et al: c-erb B-2 protein expression in node negative breast cancer. Ann Oncol 1:263-268, 1990
38. Borg A, Baldetorp B, Ferno M, et al: erb B2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143, 1991
39. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944-948, 1991
40. Lovekin C, Ellis IO Locker A, et al: c-erb B-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
41. O'Reilly SM, Barnes DM, Camplejohn RS, et al: The relationship between c-erb B-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63:444-446, 1991
42. Berns PMJJ, Klijn JGM, Van Putten WLJ, et al: c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52:1107-1113, 1992
43. Battifora H, Gaffey M, Esteban J, et al: Immunohistochemical assay of neu/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases. J Mod Pathol 4:466-474, 1991
44. Van de Vijver MJ, Peterse JL, Mooi WJ, et al: neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-1245, 1988
45. Muss HB, Thor AD, Berry DA, et al: cerb B-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994
46. Wright C, Nicholson S, Angus B, et al: Relationship between c-erb B-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
47. Borg A, Baldetorp B, Ferno M, et al: erb B2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144 1994
48. Berns EMJJ, Foekens JA, van Staveren IL, et al: Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene 159:11-18, 1995
49. Bacus S, Bacus J, Slamon DJ, et al: HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med 114:164-169, 1990